References

1. Calderón MA, Linneberg A, Kleine-Tebbe J, et al. Respiratory allergy caused by house dust mites: What do we really know? J Allergy Clin Immunol. 2015;136(1):1:38-48.

2. Portnoy J, Miller JD, Williams PB, et al. Environmental assessment and exposure control of dust mites: a practice parameter. Ann Allergy Asthma Immunol. 2013;111(6):465-507.

3. Calderón MA, Kleine-Tebbe J, Linneberg A, et al. House dust mite respiratory allergy: An overview of current therapeutic strategies. J Allergy Clin Immunol Pract. 2015;3(6):843-855. 

4. Han DH and Rhee C-S. Sublingual immunotherapy in allergic rhinitis. Asia Pac Allergy. 2011;1(3):123-129.

5. Sohn MH. Efficacy and safety of subcutaneous allergen immunotherapy for allergic rhinitis. Allergy Asthma Immunol Res. 2018;10(1):1-3.

6. Sivam A, Tankersley M. Perception and practice of sublingual immunotherapy among practicing allergists in the United States: A follow-up survey. Ann Allergy Asthma Immunol. 2019;122(6):623-629.e2.

7. Saporta D. Sublingual immunotherapy: a useful tool for the allergist in private practice. Biomed Res Int. 2016:9323804.

8. ODACTRAÒ [Prescribing Information]. Bedminster, NJ: ALK-Abelló A/S; 2017.

9. Nolte H, Maloney J, Nelson HS, et al. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. J Allergy Clin Immunol. 2015;135(6):1494-1501e6.

10. Demoly P, Emminger W, Rehm D, et al. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized, double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol. 2016;137(2):444-451.

11. Nolte H, Bernstein DI, Nelson HS, et al. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2016;138(6):1631-1638.

12. Van boven JF, Ryan D, Eakin MN, et al. Enhancing Respiratory Medication Adherence: The Role of Health Care Professionals and Cost-Effectiveness Considerations. J Allergy Clin Immunol Pract. 2016;4(5):835-46.

13. Levine DM, Landon BE, Linder JA. Trends in Patient-Perceived Shared Decision Making Among Adults in the United States, 2002-2014. Ann Fam Med. 2017;15(6):552-556.

14. Blaiss MS, Steven GC, Bender B, et al. Shared decision making for the allergist. Ann Allergy Asthma Immunol. 2018;pii:S1081-1206(18)30710-30715.

15. Bender BG and Lockey RF. Solving the problem of nonadherence to immunotherapy. Immunol Allergy Clin North Am. 2016;36(1):205-213.